Core Insights - Immunocore will present five-year overall survival data for KIMMTRAK at the 2026 AACR meeting, marking the longest OS follow-up in a randomized trial for metastatic uveal melanoma patients [1][2] Company Overview - Immunocore Holdings plc is a commercial-stage biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases [1][14] - The company’s proprietary T cell receptor technology has led to the creation of ImmTAC molecules, designed to redirect the immune system to target and kill cancer cells [3][14] Product Information - KIMMTRAK (tebentafusp-tebn) is a bispecific protein targeting gp100, approved for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in multiple regions including the US and EU [5][14] - Uveal melanoma is a rare and aggressive form of melanoma, with up to 50% of patients developing metastatic disease, historically lacking approved treatments until KIMMTRAK [4][5] Clinical Data Presentation - The presentation will include additional data beyond the abstract, such as subsequent treatments, treatment beyond progression, and prognostic factors [2][3] - The session will be held on April 19, 2026, with Paul Nathan as the presenting author [3]

4Q & FY 2025 Financial Results & Business Update To add/change the picture: Transformative immunomodulating medicines for patients • Click on the image and press BACKSPACE or DELETE on the keyboard > Click on the icon at the centre of the placeholder > Select the chosen image • To adjust the crop, right-click on the image > Crop • If for any reason the image placeholder loses the rounded shape, click on Reset button in the Home tab at the top. To add/change the picture: • Click on the image and press BACKSP ...

Core Insights - Er-Kim has been appointed by Immunocore as the distribution and commercialization partner for KIMMTRAK in Turkey and the MENA, Caucasus, and CIS regions [1][3] - KIMMTRAK is a treatment for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, a rare and aggressive form of melanoma [1][2][4] - The partnership aims to improve access to innovative cancer treatments in regions with high unmet medical needs [3] Company Overview - Er-Kim, established in 1981, specializes in biopharmaceutical innovation and has partnered with over 40 global leaders [3] - The company has a reach of over 600 million patients and generates revenues exceeding EUR 305 million [3] - Er-Kim employs over 300 professionals worldwide and focuses on sustainable and flexible business models [3] Product Information - KIMMTRAK (tebentafusp) is approved in certain countries as a monotherapy for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma [4] - The availability and prescribing conditions for KIMMTRAK may vary by country [4]

Core Insights - Immunocore reported a strong revenue performance in Q1 2025, with net revenues of $93.9 million, reflecting a 33% year-over-year growth, primarily driven by the sales of KIMMTRAK [1][2][3] Financial Results - Total net product revenue from KIMMTRAK was $93.9 million in Q1 2025, an increase from $70.3 million in Q1 2024, with $56.6 million generated in the United States, $32.8 million in Europe, and $4.5 million in international regions [3][24] - Research and development expenses for Q1 2025 were $56.5 million, slightly down from $57.5 million in Q1 2024, while selling, general, and administrative expenses increased to $40.2 million from $39.3 million [4][25] - The company achieved a net income of $5.0 million in Q1 2025, compared to a net loss of $24.4 million in the same period in 2024, with basic and diluted income per share at $0.10, up from a loss of $(0.49) [5][20] Product and Market Updates - KIMMTRAK is approved in 39 countries and launched in 26 countries for HLA-A*02:01 positive patients with metastatic uveal melanoma, continuing to be the standard of care in most markets [6][36] - The company is focusing on three key growth areas for KIMMTRAK: global expansion in metastatic uveal melanoma, potential expansion into second-line advanced cutaneous melanoma, and adjuvant uveal melanoma [7] - KIMMTRAK net product sales in the U.S. grew by 13% year-over-year, with increased demand driven by community outreach and new country launches in Europe and international regions [8] Research and Development Progress - Immunocore is on track for the Phase 3 TEBE-AM trial to complete enrollment in the first half of 2026 and for dose selection in the Phase 3 PRISM-MEL-301 trial in the second half of 2025 [1][14] - Initial multiple ascending dose data for the HIV functional cure candidate was presented at CROI 2025, with ongoing dose escalation [1][22] - The company is advancing its PRAME portfolio, with brenetafusp being evaluated in combination with nivolumab in a Phase 3 trial for first-line advanced cutaneous melanoma [10][15]